|
|
Blood, 15 February 2006, Vol. 107, No. 4, pp. 1546-1554.
Prepublished online as a Blood First Edition Paper on October 13, 2005; DOI 10.1182/blood-2004-10-4126.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells
Yoko Tabe,
Marina Konopleva,
Rooha Contractor,
Mark Munsell,
Wendy D. Schober,
Linhua Jin,
Yuko Tsutsumi-Ishii,
Isao Nagaoka,
Jun Igari, and
Michael Andreeff
From the Section of Molecular Hematology and Therapy, Departments of Blood and Marrow Transplantation, Biostatistics, and Applied Mathematics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Departments of Clinical Pathology and Biochemistry, Juntendo University of Medicine, Tokyo, Japan.
The multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp) is frequently implicated in cross-resistance of tumors to chemotherapeutic drugs. In contrast, acute promyelocytic leukemia (APL) cells do not express MDR1 and are highly sensitive to anthracyclines. The combination of ATRA and the novel histone deacetylase inhibitor (HDACI) depsipeptide (FK228) induced P-gp expression and prevented growth inhibition and apoptosis in NB4 APL cells subsequently exposed to doxorubicin (DOX). ATRA/FK228 treatment after exposure to DOX, however, enhanced apoptosis. Both agents, ATRA or FK228, induced MDR1 mRNA. This effect was significantly enhanced by ATRA/FK228 administered in combination, due in part to increased H4 and H3-Lys9 acetylation of the MDR1 promoter and recruitment of the nuclear transcription factor Y alpha (NFYA) transcription activator to the CCAAT box. Cotreatment with specific P-gp inhibitor PSC833 reversed cytoprotective effects of ATRA/FK228. G1 cell-cycle arrest and p21 mRNA induction were also observed in response to ATRA/FK228, which may restrict DOX-induced apoptosis of cells in G2 phase. These results indicate that epigenetic mechanisms involving NF-YA transcription factor recruitment and histone acetylation are activated by ATRA and HDACI, induce MDR1 in APL cells, and point to the critical importance of mechanism-based sequential therapy in future clinical trials that combine HDAC inhibitors, ATRA, and anthracyclines.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. L. Piekarz and S. E. Bates
Epigenetic Modifiers: Basic Understanding and Clinical Development
Clin. Cancer Res.,
June 15, 2009;
15(12):
3918 - 3926.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hauswald, J. Duque-Afonso, M. M. Wagner, F. M. Schertl, M. Lubbert, C. Peschel, U. Keller, and T. Licht
Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic Anticancer Drug Resistance Phenotype in Acute Myeloid Leukemia Cells by Modulation of Multiple ABC Transporter Genes
Clin. Cancer Res.,
June 1, 2009;
15(11):
3705 - 3715.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-N. Kim, N. H. Kim, W. Lee, D.-W. Seo, and Y. K. Kim
Histone Deacetylase Inhibitor Induction of P-Glycoprotein Transcription Requires Both Histone Deacetylase 1 Dissociation and Recruitment of CAAT/Enhancer Binding Protein {beta} and pCAF to the Promoter Region
Mol. Cancer Res.,
May 1, 2009;
7(5):
735 - 744.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Schlenk, K. Dohner, M. Kneba, K. Gotze, F. Hartmann, F. del Valle, H. Kirchen, E. Koller, J. T. Fischer, L. Bullinger, et al.
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B
Haematologica,
January 1, 2009;
94(1):
54 - 60.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K.W. To, O. Polgar, L. M. Huff, K. Morisaki, and S. E. Bates
Histone Modifications at the ABCG2 Promoter following Treatment with Histone Deacetylase Inhibitor Mirror Those in Multidrug-Resistant Cells
Mol. Cancer Res.,
January 1, 2008;
6(1):
151 - 164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. R. Fantin and V. M. Richon
Mechanisms of Resistance to Histone Deacetylase Inhibitors and Their Therapeutic Implications
Clin. Cancer Res.,
December 15, 2007;
13(24):
7237 - 7242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G Catalano, R. Poli, M. Pugliese, N. Fortunati, and G. Boccuzzi
Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines
Endocr. Relat. Cancer,
September 1, 2007;
14(3):
839 - 845.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. B. Dammer, A. Leon, and M. B. Sewer
Coregulator Exchange and Sphingosine-Sensitive Cooperativity of Steroidogenic Factor-1, General Control Nonderepressed 5, p54, and p160 Coactivators Regulate Cyclic Adenosine 3',5'-Monophosphate-Dependent Cytochrome P450c17 Transcription Rate
Mol. Endocrinol.,
February 1, 2007;
21(2):
415 - 438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
